648 results on '"McAlpine, Jessica N."'
Search Results
2. Opportunistic Salpingectomy Between 2017 and 2020: A Descriptive Analysis
3. Complications after opportunistic salpingectomy compared with tubal ligation at cesarean section: a retrospective cohort study
4. Single-cell genomic variation induced by mutational processes in cancer
5. Variability in endometrial carcinoma pathology practice: opportunities for improvement with molecular classification
6. AI-based histopathology image analysis reveals a distinct subset of endometrial cancers
7. VOLTA: an enVironment-aware cOntrastive ceLl represenTation leArning for histopathology
8. Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers
9. Harmonized molecular classification; assessment of a single-test ProMisE NGS tool
10. Molecular subtype stratified outcomes according to adjuvant therapy in endometrial cancer
11. Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase–Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type
12. Classification of Vulvar Squamous Cell Carcinoma and Precursor Lesions by p16 and p53 Immunohistochemistry: Considerations, Caveats, and an Algorithmic Approach
13. BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors
14. Targeted and shallow whole genome sequencing identifies therapeutic opportunities in p53abn endometrial cancers
15. Abstract B012: Application of shallow whole genome sequencing to identify therapeutic opportunities in p53abn endometrial cancers
16. Abstract PR002: Proteomic profiling of endometrial carcinomas
17. Abstract B026: Substratification of mismatch repair deficient (MMRd) endometrial cancers can provide prognostic and predictive refinement
18. Abstract B031: High risk no specific molecular profile (HR-NSMP) endometrial cancer can be stratified into three subgroups based on tumor grade and estrogen receptor status with differing clinicopathologic characteristics and outcomes
19. Endometrial cancer
20. Targeted Molecular Testing in Endometrial Carcinoma: Validation of a Clinically Driven Selective ProMisE Testing Protocol
21. L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile
22. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification
23. Recurrence rates and patterns of recurrence in stage IA p53abn endometrial cancer with and without myometrial invasion
24. Endometrial Carcinosarcomas are Almost Exclusively of p53abn Molecular Subtype After Exclusion of Mimics
25. Letter to the Editor—p53 Immunohistochemical Staining and TP53 Gene Mutations in Endometrial Cancer: Does Null Pattern Correlate With Prognosis?
26. Molecular characterization of invasive and in situ squamous neoplasia of the vulva and implications for morphologic diagnosis and outcome
27. Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses
28. Molecular subclassification of vulvar squamous cell carcinoma: reproducibility and prognostic significance of a novel surgical technique
29. Endometrial Carcinoma Molecular Subtype Correlates With the Presence of Lymph Node Metastases
30. p53 Immunohistochemical patterns in HPV-related neoplasms of the female lower genital tract can be mistaken for TP53 null or missense mutational patterns
31. From biobank and data silos into a data commons: convergence to support translational medicine
32. Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status
33. Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification
34. Therapeutic options for mucinous ovarian carcinoma
35. FIGO 2023 endometrial cancer staging: too much, too soon?
36. Opportunistic salpingectomy between 2017 and 2020: A descriptive analysis
37. Clinical Behavior and Molecular Landscape of Stage I p53-abnormal Low-Grade Endometrioid Endometrial Carcinomas
38. Supplementary Figures S1-S4 from The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas
39. Supplementary Tables S1-S5 from The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas
40. Data from The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas
41. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms
42. DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics
43. Probabilistic cell-type assignment of single-cell RNA-seq for tumor microenvironment profiling
44. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer
45. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma
46. FIGO 2023 endometrial cancer staging: too much, too soon?
47. Subclonal p53 immunostaining in the diagnosis of endometrial carcinoma molecular subtype.
48. The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas
49. Corrigendum to “Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death”: [Modern Pathology 36 (2023) 100085]
50. Artificial intelligence-based histopathology image analysis identifies a novel subset of endometrial cancers with distinct genomic features and unfavourable outcome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.